Work

Phase 1 study of SGN-PDL1V, a novel, investigational vedotin antibody–drug conjugate directed to PD-L1, in patients with advanced solid tumors (SGNPDL1V-001, trial in progress).

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.tps3154

Authors: Amita Patnaik, Justin A Call, Anna Spreafico, Lisle Nabell, Mingjin Yan, Andres Forero-Torres, Maura L. Gillison

Institutions: South Texas Accelerated Research Therapeutics, University Health Network, Princess Margaret Cancer Centre, University of Alabama at Birmingham, UAB Medicine, Seagen (United States), The University of Texas MD Anderson Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4281709253

Cites:

Cited by: 6

Related to: 10